News | October 02, 2008

Prehospital Recognition, Fast Track Treatment Lowers Mortality in STEMI Patients

October 3, 2008 - A Swedish study shows patients transported with ambulance due to ST-elevation myocardial infarction (STEMI), there was a significant association between early recognition and treatment followed by fast tracking to a coronary care unit (CCU) and long-term survival.

The study appears in the October issue of the International Journal of Cardiology (Volume 129, Issue 3, Pages 325-332). It compared short-term outcomes of STEMI patients who were sent to the emergency department as compared to fast-tracked patients sent directly to a CCU. It found a higher rate of and a more rapid revascularization in patients sent to CCUs.

To describe the short-and long-term outcome among patients with an, assessed and treated by the emergency medical services (EMS) in relation to whether they were fast tracked to (CCU) or admitted via the emergency department (ED).

Patients admitted to the CCU at Sahlgrenska University Hospital in Göteborg, Sweden with ST elevations on admission ECG were analyzed with respect to whether EMS fast tracked them to the CCU or the adjacent coronary angiography laboratory (261 patients) or admitted via the ED (235 patients). Researchers said the two groups were similar with regard to age and previous history, those who were fast tracked to CCU were more frequently than the ED patients diagnosed and treated as STEMI already prior to hospital admission. Reperfusion therapy was more commonly applied in the CCU group compared with the ED group (90 percent vs. 67 percent). The delay times (median) were shorter in the direct CCU group than in the ED group, with a difference of 10 minutes from the onset of symptoms to arrival in hospital and 25 minutes from hospital arrival to the start of reperfusion treatment (primary PCI or in-hospital fibrinolysis).
Patients in the direct CCU group had lower 30-day mortality (7.3 percent vs. 15.3 percent), as well as late mortality (>30 days to five years) (11.6 percent vs. 20.6 percent).
The research was conducted by the Prehospital Research Centre, University Collage of Borås, Borås, Sweden, the Institution of Internal Medicine, department of metabolism and cardiovascular research, Sahlgrenska University Hospital, Göteborg, Sweden, the department of clinical physiology, Sahlgrenska University Hospital, Göteborg, Karolinska Institution, Stockholm, Sweden, and Astra Zeneca R&D, Mölndal, Sweden.

For more information: www.internationaljournalofcardiology.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now